Geographic barriers to gynecologic oncology care affects nearly 10% of women
the ONA take:
Access to specialty care for gynecologic cancers is limited in a significant portion of the country, according to a recent study from researchers at the Perelman School of Medicine at the University of Pennsylvania.
The study reveals that 47 states have at least one county located more than 50 miles from the nearest gynecologic oncologist.
The researchers estimate than more than 7,000 women with gynecologic cancers experience distance-related barriers to specialist care.
In addition, referral network-related barriers affect access to specialist care for 15% of women. The study showed that 123 referral networks nationally do not have access to a gynecologic oncologist, and women have to travel outside of the referral network to be connected to a specialist.
The impact limited access to high-quality care has on clinical outcomes is not yet known. The researchers suggest future studies should focus on correlating poor clinical outcomes with geographic factors.
Access to specialty care for gynecologic cancers is limited in a significant portion of the country.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|